The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Open accessAbstract
Large numbers of melanoma lesions develop resistance to targeted inhibition of mutant BRAF or fail to respond to checkpoint blockade. We explored whether modulation of intratumoral antigen presenting cells (APCs) could increase responses to these therapies. Using mouse melanoma models, we found that CD103+ dendritic cells (DCs) were the only APCs transporting intact antigens to the lymph nodes and priming tumor-specific CD8+ T cells. CD103+ DCs were required to promote anti-tumoral effects upon blockade of the checkpoint ligand PDL1; however, PD-L1 inhibition only led to partial responses. Systemic administration of the cytokine Flt3L followed by intratumoral poly I:C injections expanded and activated CD103+ DC progenitors in the tumor, enhancing responses to BRAF and PD-L1 blockade and protecting mice from tumor rechallenge. Thus, the paucity of activated CD103+ DCs in tumors limits checkpoint blockade efficacy and Flt3L-poly I:C therapy can enhance tumor responses to checkpoint and BRAF blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“The low numbers of CD8+ T cells present in B16 and Braf- mutant tumors and their limited accumulation upon BRAF and/ or PD-L1 blockade might explain the reduced clinical response to these treatments, as previously suggested (Chen and Mell- man, 2013; Gajewski et al., 2013).”
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 4×
“Failure to respond to PD-L1 blockade has been shown to correlate with reduced expression of PD-L1 on tumor-infiltrating immune cells or the absence of CD8+ T cell in the tumor mass prior to treatment (Herbst et al., 2014; Tumeh et al., 2014).”
InfluentialType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Cited by
Items 101–123 of 123
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
Self-citationTrial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Moreno Ayala, M. A., Campbell, T. F., Zhang, C., Dahan, N., Bockman, A., Prakash, V., Feng, L., Sher, T., & DuPage, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.003 · Cited by 241
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice
Li, Y., Tinoco, R., Elmén, L., Segota, I., Xian, Y., Fujita, Y., Sahu, A., Zarecki, R., Marie, K., Feng, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09525-y · Cited by 212
Self-citationMyeloid cell heterogeneity in cancer: not a single cell alike
Kiss, M., Van Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.008 · Cited by 159
Plebanek, M. P., Xue, Y., Nguyen, Y.-V., DeVito, N. C., Wang, X., Holtzhausen, A., Beasley, G. M., Theivanthiran, B., & Hanks, B. A. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi4191 · Cited by 164
Zuo, B., Zhang, Y., Zhao, K., Wu, L., Qi, H., Yang, R., Gao, X., Geng, M., Wu, Y., Jing, R., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01266-8 · Cited by 155
Simonds, E. F., Lu, E. D., Badillo, O., Karimi, S., Liu, E. V., Tamaki, W., Rancan, C., Downey, K. M., Stultz, J., Sinha, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002181 · Cited by 119
Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91
“Preclinical studies showed that the therapeutic effect of anti-CTLA-4 (2) or anti-PD-L1 (8) was abrogated in cDC1-deficient Batf3 / mice.”
BackgroundDevelopment and aging of the lymphatic vascular system
González-Loyola, A., & Petrova, T. V. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.005 · Cited by 89
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Xie, Y., Wang, X., Wang, W., Pu, N., & Liu, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06422-5 · Cited by 80
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma
Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology · doi:10.1002/hep.31697 · Cited by 74
Theisen, D. J., Ferris, S. T., Briseño, C. G., Kretzer, N., Iwata, A., Murphy, K. M., & Murphy, T. L. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0138 · Cited by 66
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Aznar, M. A., Molina, C., Teijeira, A., Rodriguez, I., Azpilikueta, A., Garasa, S., Sanchez‐Paulete, A. R., Cordeiro, L., Etxeberria, I., Alvarez, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910375 · Cited by 44
Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A., & Ito, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0939 · Cited by 26
Corry, S. M., McCorry, A. M., Lannagan, T. R., Leonard, N. A., Fisher, N. C., Byrne, R. M., Tsantoulis, P., Cortes-Lavaud, X., Amirkhah, R., Redmond, K. L., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326183 · Cited by 18
Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines
Wylie, B., Ong, F., Belhoul-Fakir, H., Priebatsch, K., Bogdawa, H., Stirnweiss, A., Watt, P., Cunningham, P., Stone, S. R., & Waithman, J. (2021) · Cancers · doi:10.3390/cancers13246189 · Cited by 16
Determinants, mechanisms, and functional outcomes of myeloid cell diversity in cancer
Caronni, N., Montaldo, E., Mezzanzanica, L., Cilenti, F., Genua, M., & Ostuni, R. (2021) · Immunological Reviews · doi:10.1111/imr.12944 · Cited by 6
Metadata
- Authors
- Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., Chakarov, S., Rivera, C., Hogstad, B., Bosenberg, M., Hashimoto, D., Gnjatic, S., Bhardwaj, N., Palucka, A. K., Brown, B. D., Brody, J., Ginhoux, F., & Merad, M.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 44
- Issue
- 4
- Pages
- 924-938
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2341604280
- Cited by
- 1,201
- References
- 45
- FWCI
- 43.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.